Table 7.

Measured Utility values for Long Term Survivors compared to healthy controls and other chronic disease states.

	Method	Mean Utility± SD	N	P Value	Ref
Long Term LT survivors	SF6D	0.75±0.12	36
• Patients on Immunosuppression		0.73±0.12	28	0.12
• Patients off Immunosuppression		0.81±0.10	8
Controls, healthy adults aged 35+	SF6D	0.80±0.01	311	0.0001	(46)
Young adult survivors of lower extremity bone tumors	HUI3	0.75±0.29	28	1	(41)
Medical Expenditure Panel Survey (MEPS: Age 20–29)	SF6D	0.82±0.18	3662	0.02	(19, 39)
Adolescents with Cystic Fibrosis	SG	0.92±0.15	65	0.0001	(9)
Adolescents with IBD	SG	0.97±0.07	67	0.0001	(10)
Chronic Kidney Disease	SF6D	0.67±0.13	185	0.0007	(47)
Chronic Liver Disease	SF6D	0.71±0.1	88	0.059	(48)
Cirrhosis.	SF6D	0.64±0.2	54	0.0039	(48)
HCV	SF6D	0.67±0.16	41	0.0165	(48)
HBV	SF6D	0.78±0.14	51	0.3	(48)
Cholestatic Liver Disease	SF6D	0.68±0.16	33	0.04	(48)
12 months Post Transplant	SF6D	0.62±0.05	183	0.0001	(49)